PMID- 2847993
OWN - NLM
STAT- MEDLINE
DCOM- 19890112
LR  - 20191022
IS  - 0167-6997 (Print)
IS  - 0167-6997 (Linking)
VI  - 6
IP  - 3
DP  - 1988 Sep
TI  - A phase II trial of oral 4'demethoxydaunorubicin (DMDR) in inoperable non small 
      cell lung cancer.
PG  - 219-21
AB  - 4'Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered 
      to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were 
      stratified into good and poor risk categories and received doses of 45 mg/m2 and 
      40 mg/m2 respectively at 28 day intervals. All 22 patients were evaluable for 
      response: No tumour responses occurred. Therapy was well tolerated. Mild 
      gastrointestinal toxicity occurred in 41% of patients. Leucopenia with a wcc less 
      than 3 x 10(9)/L occurred in 33% of patients and thrombocytopenia less than 100 x 
      10(9)/L in 9%. Severe marrow toxicity was rare and there appeared to be no 
      difference in terms of toxicity between the different dose levels. DMDR appears 
      to have no useful clinical activity in NSCLC.
FAU - Presgrave, P
AU  - Presgrave P
AD  - Department of Clinical Oncology, Royal North Shore Hospital of Sydney, St. 
      Leonards, NSW, Australia.
FAU - Woods, R
AU  - Woods R
FAU - Kefford, R
AU  - Kefford R
FAU - Bell, D
AU  - Bell D
FAU - Raghavan, D
AU  - Raghavan D
FAU - Levi, J
AU  - Levi J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Antibiotics, Antineoplastic)
RN  - ZRP63D75JW (Idarubicin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Antibiotics, Antineoplastic/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Idarubicin/administration & dosage/adverse effects/*therapeutic use
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
AID - 10.1007/BF00175402 [doi]
PST - ppublish
SO  - Invest New Drugs. 1988 Sep;6(3):219-21. doi: 10.1007/BF00175402.